Accessibility StatementSkip Navigation Novartis to acquire Avidity for USD 72.00 per share in cash for total equity value of approximately USD 12.0 billion  Avidity expects to separate its early-stage precision cardiology programs into a new company ("SpinCo") Closing expected in 1H2026 subject to completion of the separation of SpinCo from Avidity and other customary closing conditions SAN DIEGO, Oct. 26, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company ...